Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on novel cancer therapies that target nuclear export dysregulation. Its lead product, XPOVIO (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor approved in the U.S. in multiple oncology indications and in various indications across more than 50 ex-U.S. territories and countries, according to company statements.
This news page aggregates company-issued updates and market disclosures related to Karyopharm. Readers can follow announcements on XPOVIO commercial performance, such as reported U.S. net product revenue and trends in license and royalty revenue from international partners, as described in the company’s earnings releases. The feed also covers progress in Karyopharm’s clinical pipeline, including multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL).
Recent news has highlighted key milestones in late-stage development, including completion of enrollment in the Phase 3 SENTRY trial (XPORT-MF-034) in myelofibrosis and ongoing enrollment in the global Phase 3 XPORT-EC-042 trial in TP53 wild-type advanced or recurrent endometrial cancer. Company releases also describe Phase 2 data in heavily pretreated myelofibrosis patients and the design of additional studies such as SENTRY-2 and XPORT-MM-031 in multiple myeloma.
In addition to clinical and commercial updates, Karyopharm’s news includes financial results, preliminary revenue disclosures, strategic financing transactions involving term loans and convertible notes, and inducement equity awards granted under its inducement stock incentive plan. Investors and observers can use this page to review the company’s own descriptions of its operational progress, financing activities and anticipated clinical catalysts as reported in press releases and referenced in SEC filings.
Karyopharm (Nasdaq: KPTI) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will host a conference call and live audio webcast at 8:00 a.m. ET to discuss results and company updates.
Dial-in numbers are provided for domestic and international callers, and accompanying slides plus an archived webcast will be available on the company’s Investor "Events & Presentations" webpage about two hours after the call.
Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,799 restricted stock units (RSUs) to four newly hired employees, effective January 31, 2026, under its 2022 Inducement Stock Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4).
Each RSU vests over three years with 33 1/3% vesting on each anniversary, conditioned on continued service through each vesting date.
Karyopharm (Nasdaq: KPTI) provided preliminary unaudited revenue estimates for 2025 and outlined 2026 objectives, including two near‑term Phase 3 data readouts. The company expects full‑year 2025 total revenue ≈ $145M and U.S. XPOVIO net product revenue ≈ $115M. Top‑line SENTRY myelofibrosis data are expected in March 2026 and top‑line XPORT‑EC‑042 endometrial cancer data are expected in mid‑2026. Cash, cash equivalents, restricted cash and investments were ≈ $64M as of December 31, 2025, with liquidity expected to fund operations into the second quarter of 2026. The company completed SENTRY enrollment (353 patients) and completed strategic financings to extend runway.
Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,533 restricted stock units (RSUs) to two newly hired employees, with a Grant Date of December 31, 2025. The awards were made under the company's 2022 Inducement Stock Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4).
Each RSU vests over three years, with 33 1/3% of the shares vesting on each consecutive anniversary of the Grant Date, subject to the recipient's continued service through each vesting date.
Karyopharm (Nasdaq: KPTI) announced that its senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m. ET.
Dr. Harrison is Professor of Myeloproliferative Neoplasms and Clinical Director at Guy's and St. Thomas' NHS Foundation Trust and is described as a leading international expert in myelofibrosis. A live webcast will be available under the company's Investor "Events & Presentations" page and will be posted for replay after the event.
Karyopharm Therapeutics (Nasdaq: KPTI) granted inducement awards to seven newly hired employees as of November 30, 2025 under its 2022 Inducement Stock Incentive Plan.
The company issued stock options to purchase an aggregate of 2,800 shares at an exercise price of $5.62 (closing price on the Grant Date) and granted an aggregate of 15,791 restricted stock units (RSUs). Options vest over four years (25% after one year, then monthly 1/48th), and RSUs vest over three years (33 1/3% each year), each subject to continued service.
Karyopharm (Nasdaq: KPTI) announced that its senior management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:30 a.m. ET in New York.
A live webcast will be available under the company’s Investor "Events & Presentations" page and the presentation will be available for replay following the event.
Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 800 restricted stock units (RSUs) to one newly hired employee, effective October 31, 2025, under the company’s 2022 Inducement Stock Incentive Plan.
The award was made as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over three years with 33 1/3% vesting on each anniversary of the grant date, subject to continued service through each vesting date.
Karyopharm (Nasdaq: KPTI) reported Q3 2025 total revenue of $44.0 million and U.S. XPOVIO net product revenue of $32.0 million (up 8.5% year-over-year). The company reaffirmed full-year 2025 revenue guidance of $140M–$155M and U.S. XPOVIO guidance of $110M–$120M. The Phase 3 SENTRY myelofibrosis trial completed enrollment with 353 patients, with top-line data expected in March 2026. R&D and SG&A full-year ranges were lowered to $235M–$245M. Karyopharm reported a Q3 net loss of $33.1M and stated existing liquidity is expected to fund operations into the second quarter of 2026.
Karyopharm (Nasdaq: KPTI) will report third quarter 2025 financial results on Monday, November 3, 2025. Management will host a conference call and live audio webcast at 8:00 a.m. ET the same day to discuss results and company updates.
Investors may join by phone at (800) 836-8184 (U.S.) or (646) 357-8785 (international) and should dial at least 10 minutes early. A live webcast and accompanying slides will be available under Events & Presentations on the company's Investor website, with an archived webcast posted about two hours after the event.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
